India Women's Health Therapeutics Market Growth, Size, Share, Trends, and Forecast 2032

The India women's health therapeutics market is projected to grow from $2.22 billion in 2022 to $5.98 billion in 2029, with a compound annual growth rate of 15.2%.

Key drivers of this growth include:

• Rising prevalence of women's health disorders like PCOS, which affects approximately 22.5% of Indian women
• Increasing sedentary lifestyle impacts, with 23% of women reporting missed periods and 18% increase in PCOS cases
• Growing focus on contraceptive drugs, which dominated the market share in 2021 due to high unintended pregnancy rates
• Shift in consumer behavior from retail to online pharmacies for purchasing medications

The COVID-19 pandemic initially caused a 4.8% market decline in 2020, with an estimated 1.3 million Indian women losing access to abortion and contraceptives during January-June 2020.

Major players in the market include:

• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Inc.
• Abbott
• Lupin
• Bayer AG

Recent strategic moves include Abbott's launch of single-dose carbetocin in 2021 for preventing postpartum hemorrhage, and Cipla's launch of Evexpert intimate wash in 2022 to expand their women's healthcare portfolio.

Report-

Fortune Business Insights - India Womens Health Therapeutics Market Size | Report [2029]

https://www.fortunebusinessinsights.com/india-women-s-health-therapeutics-market-106814